LAWRENCE, Mass., April 13, 2018 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading medical technology
company focused on advancing renal care, today announced that its
Medisystems products division has released MasterGuard Plus, its
latest innovation in AVF needle safety. MasterGuard Plus leverages
the proven safety features of Medisystems' MasterGuard needle guard
and offers new features designed to enhance dialysis staff safety
by helping to prevent needlestick injuries. More
specifically, MasterGuard Plus offers new intuitive ergonomic and
patented safety features including a redesigned needle lock
designed to increase security after retraction.
"Early customer feedback has been very positive, validating many
of the benefits we expected," said Joseph E. Turk, president
of NxStage Medical, Inc. "We are very excited to bring
these enhanced features to dialysis staff and patients, while
maintaining the ease of use that they have come to expect from
Medisystems products."
Medisystems will be showcasing MasterGuard Plus during the
American Nephrology Nurses Association Conference from April 15-17th in Las
Vegas, using virtual reality to help customers experience
the advantages of the device in 3D. For those attending, visit the
NxStage booth #307 for more information.
For more information visit www.nxstage.com/mgp or contact your
local area representative or distributor for a demonstration or
clinic evaluation.
About Medisystems
Medisystems offers products that are
designed to provide clinical, safety, and economic advantages.
Medisystems is committed to understanding our customers' needs so
our products can be efficiently implemented across care settings.
Our bloodlines, needles, and accessories are helping to move the
industry forward through safe, convenient, and cost-effective uses
across hemodialysis, apheresis, and plasma collection centers.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. NxStage also has established a small
number of dialysis clinics. For more information on NxStage and its
products and services, please visit the Company's websites at
www.nxstage.com and www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2017. NxStage is
under no obligation to (and expressly disclaims any such obligation
to) update or alter its forward-looking statements, whether as a
result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/medisystems-announces-us-release-of-masterguard-plus-300628818.html
SOURCE NxStage Medical, Inc.